Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 3/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.43 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 6/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24846662 | 0.94 | GLS (0.46) | GLSDGAT1MMEBRD4POLB | |
| SCHEMBL24953957 | 0.83 | SCD (0.46) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL24952929 | 0.83 | SCD (0.46) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL24952876 | 0.83 | SCD (0.46) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL24953915 | 0.77 | SCD (0.47) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL24953917 | 0.74 | SCD (0.49) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL24953921 | 0.74 | SCD (0.49) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL24953971 | 0.74 | SCD (0.49) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL24953825 | 0.74 | SCD (0.48) | POLBMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL24846063 | 0.73 | TSHR (0.61) | GLSDGAT1POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002336-A1 | MrgprX2 Antagonists and Uses Thereof | DERMIRA, INC. | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002336-A1 | MrgprX2 Antagonists and Uses Thereof | MRGPRX2, MRGPRX1, MRGPRX4 | GLS 1237/4885DGAT1 811/4885MME 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.